Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis

Keyphrases

• Adverse Events 12%
• Angiotensin Antagonists 12%
• Antifibrotic 12%
• Baseline Period 25%
• Clinical Trials 12%
• Decline Rate 12%
• Dyspepsia 12%
• Egfr 12%
• Focal Segmental Glomerulosclerosis 100%
• Hepatic Cirrhosis 12%
• Kidney Disease Progression 12%
• Monthly Changes 25%
• Multiple Sclerosis 12%
• Open-label Trial 12%
• Patient-completed 12%
• Phototoxic Dermatitis 12%
• Pirfenidone 100%
• Placebo-controlled Trial 12%
• Proteinuria 12%
• Pulmonary Fibrosis 25%
• Renal Fibrosis 12%
• Renal Function 12%
• Renal Function Decline 100%
• Sedation 12%
• Treatment Duration 12%

Medicine and Dentistry

• Adverse Event 12%
• Angiotensin Antagonist 12%
• Antifibrotic Agent 12%
• Chronic Kidney Disease 12%
• Clinical Trial 12%
• Dermatitis 12%
• Focal Segmental Glomerulosclerosis 100%
• Kidney Fibrosis 12%
• Kidney Function 100%
• Liver Cirrhosis 12%
• Multiple Sclerosis 12%
• Open-Label Trial 12%
• Pirfenidone 100%
• Placebo 12%
• Proteinuria 12%
• Pulmonary Fibrosis 25%
• Stomach Acid 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Adverse Event 12%
• Angiotensin Antagonist 12%
• Antifibrotic Agent 12%
• Chronic Kidney Failure 12%
• Clinical Trial 12%
• Dermatitis 12%
• Focal Glomerulosclerosis 100%
• Kidney Fibrosis 12%
• Liver Cirrhosis 12%
• Lung Fibrosis 25%
• Multiple Sclerosis 12%
• Open-Label Trial 12%
• Pirfenidone 100%
• Placebo 12%
• Proteinuria 12%
• Stomach Acid 12%